Among cancer immunotherapies, immune checkpoint blockade (ICB) which targets cytotoxic T lymphocyte antigen 4 (CTLA-4) or the programmed cell death 1 (PD1)–programmed cell death ligand 1 (PD­L1) axis has been approved for the treatment of several different cancer types (4–7). Here, PDCD1 is linked to cancer.